LOS ANGELES--(EON: Enhanced Online News)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Amphastar Pharmaceuticals, Inc. (“Amphastar” or the “Company”) (Nasdaq: AMPH) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at email@example.com.
Amphastar revealed that its subsidiary company Armstrong Pharmaceuticals, Inc. ("Armstrong") received a notice from the U.S. Food and Drug Administration ("FDA"), informing Armstrong that its New Drug Application for Primatene Mist, intended as an epinephrine inhalation aerosol product, cannot be approved. The FDA suggested that Armstrong should implement changes to the product's label and packaging. The FDA further suggested that Armstrong conduct another Human Factor validation study to measure consumers' ability to use the product independently of a doctor or pharmacist.
When this news was released to the public, Amphastar’s stock fell in value, causing investors harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.